Bárbara Melão, MD, PhD
@bavilima
Followers
773
Following
3K
Media
127
Statuses
1K
Urologist; Oncology Department @HAManaus; Former Fellow at @UrologyMSK #ASCO25 COI: https://t.co/NwRW5aQR3p
Joined March 2011
So honored to serve as a Featured Voice for #ASCO25 among amazing colleagues ✨ Excited to share the latest data and key takeaways from the meeting @OncBrothers @yekeduz_emre @drenriquegrande @DRBakaloudiMD @realbowtiedoc @ReginaBarCar @crisbergerot @ReneeSaliby @MikeSerzanMD
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
1
3
28
Great #ESMO25 coverage from this amazing @OncoAlert team🚨 Stay tuned ‼️ @OncoAlert @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth
We are in Berlin for #ESMO25 The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 . We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
0
4
7
🟠 LBA109 – DISCUS: 3 vs 6 cycles of platinum-based chemotherapy before Avelumab maintenance in advanced urothelial carcinoma 👨⚕️ Presented by Dr. Enrique Grande (@drenriquegrande) #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ Phase II DISCUS compared 3 vs 6 cycles of platinum-based
1
19
33
🟠 LBA108 – POTOMAC: Durvalumab + BCG vs BCG alone in BCG-naïve high-risk NMIBC 👩⚕️ Presented by Dr. Maria De Santis #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ POTOMAC (Phase III, randomized, open-label, international) evaluated Durvalumab + BCG induction + maintenance (I+M) vs BCG
0
11
39
At @myESMO #esmo2025 Berlin, I had the privilege to present the #ALBAN trial (GETUG–AFU 37), an academic phase III study led by @AFUrologie & @GETUG_Unicancer @LaCarine1 together with my outstanding co-PI @y_loriot ,co-investigators @PignotG @champiatMD @PrRomainMATHIEU
7
26
75
💥 The @OncoAlert #GUOncology team has once again delivered an outstanding lineup! 🙌 Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪 From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever. Which one are you most looking forward to? 💬 🌍
0
11
32
🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 https://t.co/BYx1L9i7GC
@PCFnews @OncoAlert @urotoday
4
70
132
Always amazing to learn from brilliant @ReginaBarCar 👏✨ #AI in Advanced #ProstateCancer
@OncoAlert @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett
2
4
17
🚨 The #OncoAlert Breast Faculty, led by Dr. Elisa Agostinetto 🇧🇪, unveils the 🔟 must-watch #BreastCancer abstracts at #ESMO25 🧠💥 🎯 Top Picks: 1️⃣ DESTINY-Breast11 – T-DXd ± THP in neoadjuvant HER2+ eBC (291O) 2️⃣ DESTINY-Breast05 – T-DXd vs T-DM1 post-NAT (LBA1) 3️⃣ ASCENT-03
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin 🔹 DESTINY-Breast11 – Neoadjuvant T-DXd ± THP vs SOC for high-risk HER2+ eBC (291O) 🔹 DESTINY-Breast05 – T-DXd
0
14
37
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin 🔹 DESTINY-Breast11 – Neoadjuvant T-DXd ± THP vs SOC for high-risk HER2+ eBC (291O) 🔹 DESTINY-Breast05 – T-DXd
4
37
74
#SurvOnc study in @JAMANetworkOpen Cancer survivors have ⬆️ use meds 💊 for #depression #anxiety vs noncancer peers: Disparaties exist. Ethnicity, nsurance, marital status, and cancer type all impact treatment #pallonc 🔗: https://t.co/j1DKYh1OiG
@PallOncCoP
@OncoAlert🚨
0
9
26
🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
9
90
198
#ProstateCancer ✨ARON-3 : 177Lu-PSMA outperforms cabazitaxel w/ higher responses, longer survival & similar safety in PC
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 19-25, 2025 REGISTER at https://t.co/yzt83gqQkF OR https://t.co/dq8GEzl9ps Discussing: ✅evERA Update : Oral SERD giredestrant + everolimus improves PFS in ER+/HER2– advanced Breast #Cancer ✅FDA
0
1
8
🚨New episode alert! Jonathan Rosenberg joins the discussion in this 2-part series on the history of IO-based therapy in Urothelial Cancer. You don't want to miss it. 🎙️ GU Oncology Now: https://t.co/2yYS1PKIHt 🍎 Apple Podcasts: https://t.co/ATWpCQE5o4 🎧Spotify:
1
16
35
Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals https://t.co/2X7x715wMC Study explored barriers and facilitators to prostate cancer screening among Black individuals in the US🇺🇸, a population with twice the mortality risk compared
0
9
12
Join us for an engaging discussion on rPFS as a surrogate for OS in patients with mHSPC 👉 https://t.co/1SFJ56eLiX Hosted by Dr. Neal Shore ( @CURCMB ) and Dr. Alicia Morgans @CaPsurvivorship (Dana-Farber Cancer Institute, Boston, MA @DanaFarber ) and brought to you by
0
3
8
Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through @costplusdrugs @mcuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up? #OncTwitter #gusm @JCOGO_ASCO
13
91
279
For THIS Weeks @oncoalert 🚨 @vjoncology JOURNAL CLUB: A pleasure to present @PGrivasMDPhD of @fredhutch discussing his paper on Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of
0
16
28
Happy to share our latest work, just published in JAMA 👉 Validation in the PLCO Cancer Screening Trial cohort of the recommendation to repeat PSA before biopsy: ✨ 50% of patients showed a PSA decline on subsequent tests ✨ 22% of patients with elevated PSA showed a decline
Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing https://t.co/PwRat6DjcG This retrospective analysis of the PLCO Cancer Screening Trial examined yearly PSA variability in over 11,000 men undergoing annual screening. The study found that a substantial
1
7
20
On my way home to #Indiana but had an outstanding time sharing my passions for #EarlyCareer to so many resident, students and fellows at #TxSCO25. Thanks for the opportunity @OSSatACCC #MedEd #ProfDev
2
4
43
🚨 New Oncology Journal Club @OncoAlert & @VJOncology proudly present Dr. Rinath Jeselsohn (@DanaFarber) as she presents key findings from the PACE trial, exploring ctDNA dynamics in patients with HR+/HER2- metastatic #BreastCancer Article Found Here 👉 https://t.co/JCqjaJDzt2
0
18
27